Details for Patent: 10,117,836

✉ Email this page to a colleague

Which drugs does patent 10,117,836 protect, and when does it expire?

Patent 10,117,836 protects QULIPTA and UBRELVY and is included in two NDAs.

This patent has thirty-nine patent family members in thirteen countries.

Summary for Patent: 10,117,836

Scope and claims summary:

Title:	Tablet formulation for CGRP active compounds
Abstract:	The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein "R.sup.a" is independently H or --F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released. ##STR00001##
Inventor(s):	Johnson; Mary Ann (West Point, PA), Allain; Leonardo Resende (Lansdale, PA), Eickhoff; W. Mark (Lansdale, PA), Ikeda; Craig B. (Harleysville, PA), Brown; Chad D. (Quakertown, PA), Flanagan, Jr.; Francis J. (North Wales, PA), Nofsinger; Rebecca (Lansdale, PA), Marota; Melanie (Lansdale, PA), Lupton; Lisa (South San Francisco, CA), Patel; Paresh B. (Langhorne, PA), Xi; Hanmi (Furlong, PA), Xu; Wei (North Wales, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	15/115,026
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,117,836
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 10,117,836

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	10,117,836	⤷ Subscribe	Y				⤷ Subscribe
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-002	Sep 28, 2021		RX	Yes	No	10,117,836	⤷ Subscribe	Y				⤷ Subscribe
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-003	Sep 28, 2021		RX	Yes	Yes	10,117,836	⤷ Subscribe	Y				⤷ Subscribe
Abbvie	UBRELVY	ubrogepant	TABLET;ORAL	211765-001	Dec 23, 2019		RX	Yes	No	10,117,836	⤷ Subscribe	Y				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,117,836

PCT Information
PCT Filed	January 30, 2015	PCT Application Number:	PCT/US2015/013672
PCT Publication Date:	August 13, 2015	PCT Publication Number:	WO2015/119848

International Family Members for US Patent 10,117,836

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015214502	⤷ Subscribe
Australia	2019226239	⤷ Subscribe
Australia	2021245229	⤷ Subscribe
Australia	2021409718	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.